SIRT1 and metabolic dysfunction-associated steatotic liver disease: Together, these data suggested that SIRT1 is a target of miR-34a and that CA-mediated inhibition of miR-34a confers protection against NAFLD, which is related to the activation of the SIRT1/p66shc signaling pathway.